Puma Biotechnology (NASDAQ:PBYI) First Quarter 2024 Results

Key Financial Results

• Revenue: US$43.8m (down 17% from 1Q 2023).

• Net loss: US$4.80m (down by 443% from US$1.40m profit in 1Q 2023).

• US$0.10 loss per share (down from US$0.03 profit in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Puma Biotechnology EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 54%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 3.2% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Puma Biotechnology has 3 warning signs (and 1 which is potentially serious) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.